Photo: Female researcher looking through microscope

Anti-LINGO-1

Anti-LINGO-1 (opicinumab or BIIB033) is a myelin repair treatment being developed by Biogen.

Current phase of trial: phase 2

Type of MS: relapsing MS.

About Anti-LINGO-1